POSB125 The Impact of Discounting on the Cost Effectiveness of Tisagenlecleucel for Relapsed/Refractory Acute Lymphoblastic Leukaemia
- Resource Type
- Abstract
- Source
- In
Value in Health January 2022 25(1) Supplement:S85-S86 - Subject
- Language
- ISSN
- 1098-3015